PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials

Authors

  • Phan Nguyen Nhu Quynh School of Medicine, Vietnam National University, Ho Chi Minh City, Viet Nam
  • Phuong Thi Lan Nguyen School of Medicine, Vietnam National University, Ho Chi Minh City, Viet Nam
  • Ha Thi Nguyen School of Medicine, Vietnam National University, Ho Chi Minh City, Viet Nam
  • Toi Lam Phung Health Strategy and Policy Institute, Ministry of Health, Hanoi, Viet Nam
  • Danielle TuongVy Nguyen Department of Pharmacotherapy, College of Pharmacy, University of Utah, Utah, USA
  • Khanh Ngoc Cong Duong School of Medicine, Vietnam National University, Ho Chi Minh City, Viet Nam; Department of Pharmacotherapy, College of Pharmacy, University of Utah, Utah, USA https://orcid.org/0000-0002-7152-9476

DOI:

https://doi.org/10.15419/bmrat.v10i12.851

Keywords:

Ovarian cancer, Poly (ADP-ribose) polymerase inhibitors, PARP inhibitors, clinical trial, Systematic review

Abstract

Objective: This review aimed to systematically synthesize and report the clinical outcomes of poly-ADP ribose polymerase inhibitors (PARPis) for maintenance therapy among ovarian cancer (OC) patients.

Methods: This review was based on the updated PRISMA statement 2020. Eligible studies were identified from PubMed and the Cochrane Library from the database inception to October 7, 2021. Randomized controlled trials reporting the clinical outcomes of PARPis as maintenance therapy for OC were included in this review. The Risk of Bias 2 tool was used for the quality assessment of studies.

Results: Out of 26 studies, 10 were eligible. For patients with newly diagnosed disease, compared with placebo, either olaparib or niraparib considerably prolonged progression-free survival (PFS), with hazard ratios (HRs) of 0.59 (95% confidence interval [CI]: 0.49–0.72) and 0.62 (95% CI: 0.50–0.76), respectively. Among recurrent patients, olaparib, niraparib, and rucaparib also achieved higher PFS than placebo, with HRs of 0.39 (95% CI: 0.27–0.55), 0.32 (95% CI: 0.23–0.45), and 0.35 (95% CI: 0.28–0.45), respectively. Regarding adverse events, patients taking PARPis experienced a higher risk of hematologic events than the placebo group.

Conclusions: PARPis as maintenance therapy were beneficial in PFS improvement for OC patients. However, the considerable risk of hematologic events must be considered when using this treatment class.

Published

2023-12-31

Issue

Section

Review

How to Cite

PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials. (2023). Biomedical Research and Therapy, 10(12), 6090-6102. https://doi.org/10.15419/bmrat.v10i12.851

Similar Articles

1-10 of 476

You may also start an advanced similarity search for this article.